TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline, an Alpha 4 Beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, on Cognitive Dysfunction in 120 Patients With Schizophrenia: a Randomized, Double Blind, 8 Weeks Trial
Brief Summary: The primary objective of this project is to examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia. The secondary objective is to evaluate the effect of this combination therapy on smoking in people with schizophrenia. This study will be a randomized, double blind, parallel group, placebo controlled 8 weeks trial.


Options:
A: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
B: Arm Label: Effectiveness of Nicotine patch only; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: Effectiveness of Combination NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine lozenge, Drug: Nicotine Patch | Arm Label: Effectiveness of Varenicline [Chantix]; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Effectiveness of Varenicline [Chantix] | Intervention Type: DRUG; Name: Nicotine lozenge; Assigned to Arm(s): Effectiveness of Combination NRT | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Effectiveness of Combination NRT, Effectiveness of Nicotine patch only
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Nicotine patch plus placebo gum; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Behavior Therapy for alcohol and smoking cessation, Drug: Nicoderm CQ nicotine patch, Drug: Placebo gum | Arm Label: Nicotine patch plus active gum; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavior Therapy for alcohol and smoking cessation, Drug: Nicoderm CQ nicotine patch, Drug: Nicotine gum - Nicorette® | Intervention Type: BEHAVIORAL; Name: Cognitive Behavior Therapy for alcohol and smoking cessation; Assigned to Arm(s): Nicotine patch plus active gum, Nicotine patch plus placebo gum | Intervention Type: DRUG; Name: Nicoderm CQ nicotine patch; Assigned to Arm(s): Nicotine patch plus active gum, Nicotine patch plus placebo gum | Intervention Type: DRUG; Name: Placebo gum; Assigned to Arm(s): Nicotine patch plus placebo gum | Intervention Type: DRUG; Name: Nicotine gum - Nicorette®; Assigned to Arm(s): Nicotine patch plus active gum

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline, an Alpha 4 Beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, on Cognitive Dysfunction in 120 Patients With Schizophrenia: a Randomized, Double Blind, 8 Weeks Trial
Brief Summary: The primary objective of this project is to examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia. The secondary objective is to evaluate the effect of this combination therapy on smoking in people with schizophrenia. This study will be a randomized, double blind, parallel group, placebo controlled 8 weeks trial.


Options:
A: Arm Label: Treatment as Usual Group 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment as Usual Group 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group 1; Type: EXPERIMENTAL; Interventions: Behavioral: Computer Screening, Brief Intervention, Referral toTreatment | Arm Label: Intervention Group 2; Type: EXPERIMENTAL; Interventions: Behavioral: Computer Screening, Brief Intervention, Referral toTreatment | Intervention Type: BEHAVIORAL; Name: Computer Screening, Brief Intervention, Referral toTreatment; Assigned to Arm(s): Intervention Group 1, Intervention Group 2
B: Arm Label: Brief Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Bupropion/Low Contact; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Placebo/Low Contact; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Bupropion/High Contact; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Placebo/High Contact; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bupropion and NRT | Intervention Type: DRUG; Name: Bupropion and NRT; Assigned to Arm(s): Brief Treatment, Extended Bupropion/High Contact, Extended Bupropion/Low Contact, Extended Placebo/High Contact, Extended Placebo/Low Contact
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 300 mg/day bupropion-sr | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0 mg/day bupropion-sr | Intervention Type: DRUG; Name: 300 mg/day bupropion-sr; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 0 mg/day bupropion-sr; Assigned to Arm(s): 2
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline, an Alpha 4 Beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, on Cognitive Dysfunction in 120 Patients With Schizophrenia: a Randomized, Double Blind, 8 Weeks Trial
Brief Summary: The primary objective of this project is to examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia. The secondary objective is to evaluate the effect of this combination therapy on smoking in people with schizophrenia. This study will be a randomized, double blind, parallel group, placebo controlled 8 weeks trial.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chantix, Behavioral: Standard Counseling | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Behavioral: Adherence Counseling, Behavioral: Standard Counseling | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Adherence Counseling; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Standard Counseling; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Prospective, Randomized, Open-label Study With Blinded Outcome Evaluation to Evaluate the Effects of Systolic Blood Pressure Lowering to Different Targets (Less Than 130 mmHg vs. Less Than 140 mmHg) on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction
Brief Summary: The purpose of this study is to determine the effects of treatment with valsartan + amlodipine to a target systolic blood pressure (SBP)\<130 mmHg compared to the Joint National Commission on the Treatment of Hypertension 7 recommended target SBP of \<140 mmHg on the intrinsic diastolic properties of the myocardium in patients with hypertension and echocardiographic evidence of diastolic dysfunction.


Options:
A: Arm Label: Standard treatment regimen; Type: EXPERIMENTAL; Interventions: Drug: valsartan, Drug: amlodipine | Arm Label: Intensive treatment regimen; Type: EXPERIMENTAL; Interventions: Drug: valsartan, Drug: amlodipine | Intervention Type: DRUG; Name: valsartan; Assigned to Arm(s): Intensive treatment regimen, Standard treatment regimen | Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): Intensive treatment regimen, Standard treatment regimen
B: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet
C: Arm Label: 'Less tight' control.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intervention is blood pressure management approach | Arm Label: 'Tight' control.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intervention is blood pressure management approach. | Intervention Type: PROCEDURE; Name: Intervention is blood pressure management approach; Assigned to Arm(s): 'Less tight' control. | Intervention Type: PROCEDURE; Name: Intervention is blood pressure management approach.; Assigned to Arm(s): 'Tight' control.
D: Arm Label: strict control; Type: ACTIVE_COMPARATOR; Interventions: Other: target blood pressure | Arm Label: moderate control; Type: ACTIVE_COMPARATOR; Interventions: Other: target blood pressure | Intervention Type: OTHER; Name: target blood pressure; Assigned to Arm(s): moderate control, strict control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled Clinical Trial of Catheter Cryoablation in the Treatment of Paroxysmal Atrial Fibrillation.
Brief Summary: This study (STOP AF) is a prospective, randomized, controlled, multicenter, pivotal clinical investigation conducted at 26 investigational sites in the United States and Canada. Subjects with paroxysmal atrial fibrillation (PAF) referred for ablative intervention after efficacy failure of one or more Study Atrial Fibrillation (AF) Drugs (flecainide, propafenone or sotalol) were randomized 2:1 to cryoablation intervention (Experimental Subjects, ES) or to a Study AF Drug (Control Subjects, CS). Subjects were followed for 12 months with scheduled and symptom-driven assessments to detect recurrent atrial fibrillation by means of periodic electrocardiograms, weekly scheduled trans-telephonic monitoring, patient-initiated trans-telephonic monitoring, and 24-hour Holter monitoring at 6 and 12 months. The first 90 days after study therapy was initiated was considered a blanked period for all subjects.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radiofrequency ablation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Radiofrequency ablation | Intervention Type: PROCEDURE; Name: Radiofrequency ablation; Assigned to Arm(s): 1, 2
B: Intervention Type: PROCEDURE; Name: Circumferential Pulmonary Vein Ablation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Antiarrhythmic Drug Therapy; Assigned to Arm(s): N/A
C: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Device: Arctic Front® Cryoablation Catheter | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flecainide or Sotalol or Propafenone | Intervention Type: DEVICE; Name: Arctic Front® Cryoablation Catheter; Assigned to Arm(s): Experimental | Intervention Type: DRUG; Name: Flecainide or Sotalol or Propafenone; Assigned to Arm(s): Control
D: Arm Label: Drug Treatment; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Drug: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs | Arm Label: ThermoCool Radiofrequency Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Device: ThermoCool Radiofrequency Catheter | Intervention Type: DEVICE; Name: Radiofrequency ablation, antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment, ThermoCool Radiofrequency Catheter | Intervention Type: DRUG; Name: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment | Intervention Type: DEVICE; Name: ThermoCool Radiofrequency Catheter; Assigned to Arm(s): ThermoCool Radiofrequency Catheter

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24 Week, Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of 18 MCG of Tiotropium Inhalation Capsules Administered by HandiHaler Once-daily Plus PRN Albuterol (Salbutamol) vs. Placebo Plus PRN Albuterol (Salbutamol) in Chronic Obstructive Pulmonary Disease Subjects Naive to Maintenance Therapy
Brief Summary: A 24 week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 18mcg of tiotropium inhalation capsules administered by Handihaler once daily plus Pro Re Nata (PRN) albuterol (salbutamol) vs. placebo plus PRN albuterol (salbutamol) in chronic obstructive pulmonary disease subjects naive to maintenance therapy.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: tiotropium; Type: EXPERIMENTAL; Interventions: Drug: tiotropium | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Intervention Type: DEVICE; Name: Pulmonary function Testing; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tiotropium bromide; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: SPIRIVA; Assigned to Arm(s): N/A
D: Arm Label: Tiotropium; Type: OTHER; Interventions: Drug: Tiotropium | Arm Label: Placebo; Type: OTHER; Interventions: Device: Respimat | Intervention Type: DEVICE; Name: Respimat; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single-centre, Randomised, Single-blind, Parallel Group Clinical Trial in Rural Malawi, Testing the Growth Promoting Effect of Long-term Complementary Feeding of Infants With a High-energy, Micronutrient Fortified Spread
Brief Summary: This study tests the hypothesis that infants receiving milk-powder containing fortified spread (lipid-based nutrient supplement) as a complementary food for one year have lower incidence of severe stunting (poor length gain) than infants who are provided with no extra food supplements or maize-soy flour for complementary porridge.


Options:
A: Arm Label: ST-DI; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: FSm; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Milk-containing fortified spread | Arm Label: FSs; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Soy-containing fortified spread | Arm Label: LP; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Maize-soy flour | Intervention Type: DIETARY_SUPPLEMENT; Name: Milk-containing fortified spread; Assigned to Arm(s): FSm | Intervention Type: DIETARY_SUPPLEMENT; Name: Soy-containing fortified spread; Assigned to Arm(s): FSs | Intervention Type: DIETARY_SUPPLEMENT; Name: Maize-soy flour; Assigned to Arm(s): LP
B: Arm Label: Intervention participant; Type: EXPERIMENTAL; Interventions: Other: Counseling and nutrition supplement | Intervention Type: OTHER; Name: Counseling and nutrition supplement; Assigned to Arm(s): Intervention participant
C: Arm Label: MSPP Integrated Package; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Nutributter 3 Months, Integrated Package; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutributter Program, Other: Integrated Package | Arm Label: Nutributter 6 Months, Integrated Package; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutributter Program, Other: Integrated Package | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutributter Program; Assigned to Arm(s): Nutributter 3 Months, Integrated Package, Nutributter 6 Months, Integrated Package | Intervention Type: OTHER; Name: Integrated Package; Assigned to Arm(s): Nutributter 3 Months, Integrated Package, Nutributter 6 Months, Integrated Package
D: Intervention Type: DIETARY_SUPPLEMENT; Name: PlumpyNut; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: PlumpyDoz; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind Placebo Controlled Randomized Trial of Montelukast in Acute Respiratory Syncytial Virus Bronchiolitis
Brief Summary: There is evidence of inflammatory mechanisms in RSV bronchiolitis with increased cysteinyl-leukotrienes (cys-LT). Recently, specific cys-LT receptor antagonists - montelukast (Singulair©) approved for use in infants as granule sachets, have become available. We evaluated the effect of Singulair© on clinical progress and on cytokine profiles in the acute phase of RSV bronchiolitis.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Montelukast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo granules | Intervention Type: DRUG; Name: Montelukast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo granules; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A
C: Arm Label: montelukast; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): montelukast
D: Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: placebo; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of the Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil Vaccine to Prevent HPV Infection
Brief Summary: To demonstrate that Gardasil® vaccine, when given to girls 11-13 years of age according to 1 of 3 alternative 3-dose schedules (0, 3, 9 months; 0, 6, 12 months; or 0, 12, 24 months), results in anti-HPV type 16 and anti-HPV type 18 responses 28 days post-dose 3 that are similar to those obtained when the vaccine is given on the standard 3-dose schedule of 0, 2, 6 months.


Options:
A: Arm Label: 0,2,6 month vaccination schedule; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Arm Label: 0,3,9 month vaccination schedule; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Arm Label: 0,6,12 month vaccination schedule; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Arm Label: 0,12,24 month vaccination schedule; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Intervention Type: BIOLOGICAL; Name: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Assigned to Arm(s): 0,12,24 month vaccination schedule, 0,2,6 month vaccination schedule, 0,3,9 month vaccination schedule, 0,6,12 month vaccination schedule
B: Arm Label: Cervarix 2 dose Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Gardasil 2 dose Group; Type: EXPERIMENTAL; Interventions: Biological: Gardasil, Drug: Placebo | Arm Label: Gardasil 3 dose Group; Type: EXPERIMENTAL; Interventions: Biological: Gardasil | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix 2 dose Group | Intervention Type: BIOLOGICAL; Name: Gardasil; Assigned to Arm(s): Gardasil 2 dose Group, Gardasil 3 dose Group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cervarix 2 dose Group, Gardasil 2 dose Group
C: Arm Label: Cervarix; Type: ACTIVE_COMPARATOR; Interventions: Biological: Cervarix | Arm Label: Gardasil; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gardasil | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix | Intervention Type: BIOLOGICAL; Name: Gardasil; Assigned to Arm(s): Gardasil
D: Arm Label: qHPV Vaccine; Type: EXPERIMENTAL; Interventions: Biological: (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: placebo (unspecified) | Intervention Type: BIOLOGICAL; Name: (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Assigned to Arm(s): qHPV Vaccine | Intervention Type: BIOLOGICAL; Name: Comparator: placebo (unspecified); Assigned to Arm(s): Placebo

Answer: A